Leptin
The 167-amino-acid adipose hormone discovered in 1994 that was supposed to cure obesity — and did, for the handful of people born without it. For everyone else, the story turned out to be leptin resistance, not leptin deficiency, and the therapeutic lesson has been much harder than the biology.
What is Leptin?
Leptin is a 167-amino-acid four-helical-bundle cytokine-family hormone, product of the ob/LEP gene, secreted predominantly by white adipocytes in proportion to fat mass. It circulates at levels roughly proportional to body-fat content and signals the brain — principally the hypothalamic arcuate nucleus — about long-term energy reserves. Leptin deficiency in rare monogenic cases produces severe early-onset obesity that reverses dramatically with recombinant leptin replacement (metreleptin, FDA-approved as Myalept). Common obesity, in contrast, is a state of elevated leptin that the brain fails to respond to — the phenomenon collectively termed leptin resistance — and leptin replacement does not work in that context. The discovery of leptin in 1994 by the Friedman lab was one of the most dramatic events in metabolic medicine; the subsequent 30 years have been a case study in how a discovery of the problem does not automatically produce a therapy.
What Leptin Is Investigated For
Leptin is one of the most important endogenous peptides to understand but one of the least useful to administer. The FDA-approved indication (metreleptin, brand Myalept) is generalized lipodystrophy — a rare disorder where patients cannot produce normal adipose tissue and therefore have pathologically low leptin, with severe metabolic and fatty-liver consequences. Metreleptin reverses the metabolic picture dramatically in that population. For the much larger population of readers arriving at this page with questions about leptin and common obesity, the honest answer is that leptin replacement does not work there — obese patients already have elevated leptin, and the therapeutic problem is their brain's reduced responsiveness, not an absent signal. Low-dose leptin in the post-weight-loss state (Rosenbaum/Leibel work) has shown intriguing maintenance effects but has not become a therapy. This page is positioned as a biology reference and a reality-check on 'leptin supplements,' which are not a real category.
History & Discovery
The leptin story begins with the spontaneous ob/ob (obese) mouse mutation first described at Jackson Laboratory in 1950 and the db/db (diabetic) mutation described in 1966. Parabiosis experiments by Douglas Coleman in the 1970s established that ob/ob mice were missing a circulating factor that db/db mice could produce but not respond to — the first strong evidence for a blood-borne 'satiety hormone.' The ob gene itself remained elusive until Jeffrey Friedman's lab at Rockefeller positionally cloned it in 1994, publishing in Nature in December of that year. The product was named leptin, from Greek leptos (thin). The immediate preclinical confirmation came in 1995 — Halaas et al. showed recombinant leptin produced dramatic weight loss in ob/ob mice. The leptin receptor was cloned by Tartaglia and colleagues the same year. The first human cases of congenital leptin deficiency, identified by the Farooqi/O'Rahilly group in Cambridge in 1997, produced the extraordinary 1999 NEJM paper demonstrating reversal of severe obesity in a child given recombinant leptin. At this point the field believed it had a blockbuster coming. The Heymsfield 1999 JAMA trial of recombinant leptin in common obesity was the cold shower — doses far above physiologic produced only modest weight loss and substantial injection-site reactions, and the drug development program for common obesity effectively ended. The indication that did translate was generalized lipodystrophy, where leptin levels are pathologically low due to absence of adipose tissue — Oral et al. 2002 NEJM demonstrated dramatic reversal of the associated metabolic syndrome, and metreleptin (Myalept) received FDA approval in 2014 for that narrow indication. The lipodystrophy indication sustains the commercial product; the rest of the field has moved toward understanding leptin resistance rather than trying to overcome it with replacement.
How It Works
Leptin is the fat-mass thermostat signal. Fat cells make it in proportion to how much fat you have, and it tells the brain 'we have enough stored energy — you can stop driving appetite.' In rare people born without leptin, the brain thinks it's starving even at enormous body weight, and giving them leptin fixes it. In common obesity, the problem isn't that leptin is missing — it's that the brain has tuned out the signal. Adding more leptin to a tuned-out brain doesn't work, which is why the 'leptin cure' that seemed obvious in 1995 turned out not to be.
Leptin signals through the long-form leptin receptor (LEPR-B / ObRb), a class I cytokine receptor expressed on hypothalamic arcuate nucleus neurons including POMC/CART (anorexigenic) and NPY/AgRP (orexigenic) populations. Leptin binding drives JAK2 phosphorylation and STAT3 activation in POMC neurons, increasing transcription of POMC and its downstream cleavage products (α-MSH) that engage MC4R in the paraventricular nucleus to suppress food intake and increase energy expenditure. In NPY/AgRP neurons, leptin inhibits NPY release. The net output of leptin signaling is anorexigenic and thermogenic. Leptin resistance is best understood as a reduction in signal throughput rather than a single-step defect. SOCS3 (suppressor of cytokine signaling 3) is transcriptionally induced by STAT3 itself, providing negative feedback; chronic elevated leptin drives elevated SOCS3, which inhibits further JAK2-STAT3 signaling. PTP1B dephosphorylates JAK2 and provides a parallel negative-feedback loop. Saturable transport of leptin across the blood-brain barrier appears to have reduced capacity in obese states, so CSF leptin does not rise in proportion to serum leptin. Mediobasal hypothalamic inflammation (activated microglia, elevated IKKβ/NF-κB signaling) contributes. Downstream defects in the melanocortin pathway — particularly MC4R signaling — can produce leptin-resistance-like phenotypes independent of upstream leptin signaling itself, which is the rationale for setmelanotide as a treatment for specific monogenic obesity forms.
Evidence Snapshot
Human Clinical Evidence
Strong for the rare-disease indications: congenital leptin deficiency responds dramatically to replacement (Farooqi 1999 NEJM), and generalized lipodystrophy responds to metreleptin (Oral 2002 NEJM and follow-up). Weak for common obesity: the Heymsfield 1999 JAMA trial was the definitive negative study that ended the common-obesity development program. Emerging for post-weight-loss maintenance (Rosenbaum/Leibel).
Animal / Preclinical
Extensive. Leptin biology was characterized through the ob/ob (leptin-null) and db/db (leptin-receptor-null) mouse models over decades. Halaas 1995 Science showed dramatic weight loss with recombinant leptin in ob/ob mice — the original preclinical demonstration that ran ahead of the subsequent human disappointment in common obesity.
Mechanistic Rationale
Strong. Leptin signaling through JAK2-STAT3 and the arcuate melanocortin pathway is one of the best-characterized endocrine axes. The mechanistic story explains why common-obesity leptin replacement failed — the limitation was never on the leptin-signal side.
Research Gaps & Open Questions
What the current literature has not yet settled about Leptin:
- 01Whether low-dose leptin replacement can be developed as a post-weight-loss maintenance therapy to prevent regain — the mechanistic work supports it but no clinical program has translated the finding.
- 02The true mechanism of leptin resistance in common obesity — multiple proposed pathways (SOCS3, PTP1B, BBB transport, hypothalamic inflammation, downstream MC4R defects) likely each contribute, but relative weights remain unresolved.
- 03Whether pharmacologic agents that improve leptin sensitivity (SOCS3 inhibitors, PTP1B inhibitors, agents targeting hypothalamic inflammation) can produce clinically meaningful weight loss in common obesity.
- 04Whether the lymphoma signal in metreleptin-treated lipodystrophy patients reflects drug effect, underlying disease risk, or both.
- 05The role of partial lipodystrophy as a metreleptin indication — approved in the EU, not in the US, with ongoing evidence development.
- 06Long-term neutralizing-antibody outcomes and whether engineering variants of metreleptin can reduce immunogenicity.
- 07Whether specific genetic subtypes of common obesity (MC4R-deficient, leptin-signaling-pathway polymorphisms) respond differently to leptin replacement or to melanocortin agonists like setmelanotide.
Forms & Administration
Metreleptin (Myalept) is recombinant methionyl human leptin produced in E. coli, supplied as a lyophilized powder for subcutaneous injection. It is administered once daily, typically at the same time each day, with dose titrated to clinical response in lipodystrophy. Access in the US is restricted to prescribers and patients enrolled in the Myalept REMS program because of the antibody-formation and lymphoma signals. It is not available in compounded-peptide formularies and is not appropriate for self-administration in common obesity. Research-grade recombinant leptin exists for preclinical and investigational-use work but is not a legitimate therapeutic source.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Metreleptin for generalized lipodystrophy: weight-based starting dose of 0.06 mg/kg/day SC for patients weighing ≤40 kg, or fixed-dose 2.5 mg/day for males and 5 mg/day for females weighing >40 kg. Dose may be titrated up to 0.13 mg/kg/day (low weight) or 10 mg/day (higher weight) based on clinical response and tolerability. Research-use low-dose leptin (Rosenbaum/Leibel post-weight-loss-maintenance paradigm) has used regimens around 0.08–0.11 mg/kg/day SC.
Frequency
Once-daily subcutaneous administration at a consistent time of day is standard. Metreleptin's half-life is several hours; once-daily dosing is clinically adequate for the approved indication.
Timing Considerations
Time of day
Once daily at a consistent time — morning is common in most protocols; bedtime is used when daytime hypoglycemia is a concern in diabetic lipodystrophy patients.
Relative to meals
Not meal-timed in a clinically meaningful sense.
Relative to exercise
Not tied to exercise timing.
Consistency matters more than specific time of day. The pharmacokinetic profile of metreleptin does not produce meaningful meal-timing benefits.
Cycle Length
Indefinite for generalized lipodystrophy — metreleptin is a chronic replacement therapy, not a cycled intervention. Treatment typically continues lifelong pending alternative therapies or resolution of lipodystrophy (which essentially does not occur with current treatment options).
Protocol Notes
Metreleptin initiation in lipodystrophy patients routinely requires substantial reductions in insulin and oral antihyperglycemic therapy because of the improvement in insulin sensitivity — hypoglycemia in the first weeks is a real and anticipated issue that prescribers manage proactively. Injection-site rotation matters. Anti-metreleptin neutralizing antibodies develop in some patients over time and can reduce efficacy or, rarely, cross-react with endogenous leptin to produce a functional leptin deficiency syndrome — this is a key reason for the REMS program. There is no legitimate compounded-peptide pathway for leptin; the molecule requires Myalept as the commercial source. Low-dose leptin in the post-weight-loss state remains a research use, not an approved indication. The Rosenbaum/Leibel protocols used specific dosing to restore pre-weight-loss leptin levels and documented improvements in thyroid axis, sympathetic nervous system tone, and skeletal muscle efficiency — results consistent with leptin's role as an adiposity-proportional energy-reserve signal. No commercial therapy has emerged from this line of work.
Metreleptin is a REMS-controlled prescription medication for a specific rare indication. Nothing on this page constitutes a suggested protocol for common-obesity self-use — there is no such thing as effective leptin replacement in common obesity.
Timeline of Effects
Onset
Serum metabolic effects (triglyceride reduction, glucose improvement) begin within the first 1–4 weeks of metreleptin therapy in lipodystrophy. Appetite suppression, when it occurs, is often evident within days at full dose.
Peak Effect
Peak metabolic response in lipodystrophy typically develops over 3–6 months of continuous therapy. Hepatic fat content (MRI-PDFF) responses often lag the glucose and triglyceride improvements.
After Discontinuation
Metabolic decompensation typically returns within weeks of discontinuation in lipodystrophy patients — this is a chronic replacement therapy analogous to insulin, not a time-limited intervention. In research-use low-dose leptin for post-weight-loss maintenance, the reported physiologic effects reverse on discontinuation.
Monitoring & Measurement
Bloodwork & Labs
- •Serum leptin (ELISA — level tracks fat mass; interpretation requires body-composition context)
- •Soluble leptin receptor (sOB-R; free-leptin index calculations in research use)
- •Neutralizing anti-metreleptin antibodies (REMS program testing on metreleptin therapy)
- •Fasting glucose, HbA1c, fasting lipid panel (primary efficacy endpoints in lipodystrophy)
- •ALT/AST and MRI-PDFF for hepatic steatosis monitoring in lipodystrophy
Functional & Performance Tests
- •DEXA body composition — contextualizes serum leptin and tracks the fat-mass-proportional baseline
- •MRI fat-depot quantification in lipodystrophy characterization
When to Test
For lipodystrophy patients on metreleptin: baseline biomarker panel, 4–12 weeks post-initiation, then every 3–6 months during stable therapy. Neutralizing-antibody testing per REMS schedule. For research use or diagnostic leptin levels: fasting morning sample with standard serum handling.
Interpretation & Notes
Serum leptin has a clinically meaningful role primarily in diagnosing suspected monogenic leptin deficiency (where levels are undetectable or near-zero despite substantial adiposity) and in characterizing lipodystrophy (where levels are inappropriately low for the apparent body habitus). In common-obesity evaluation, elevated leptin is the expected finding and rarely changes management. Serum-leptin ELISAs from different manufacturers produce meaningfully different absolute values — results should be interpreted within the reporting lab's reference range and ideally tracked using the same assay platform over time.
Common Questions
Who Leptin Is NOT For
- •General obesity not associated with congenital leptin deficiency — metreleptin is not indicated and has not been shown effective.
- •Patients with hematologic abnormalities or a history of lymphoma — metreleptin carries a lymphoma warning in the lipodystrophy population, and baseline lymphoma is a contraindication.
- •Known hypersensitivity to metreleptin or E. coli-derived proteins.
- •Pregnancy — insufficient human data; metreleptin is Pregnancy Category C.
- •Patients who cannot comply with REMS program monitoring and reporting requirements.
Drug & Supplement Interactions
Metreleptin's main interaction space is insulin and oral antihyperglycemic medications — improvement in insulin sensitivity on metreleptin therapy in lipodystrophy patients frequently requires substantial reductions in these agents, and failure to anticipate this produces hypoglycemia. Prescribers routinely begin tapering insulin on day one of metreleptin initiation in previously insulin-requiring lipodystrophy patients. Leptin signaling intersects with several hypothalamic-pituitary axes (gonadal, thyroid, adrenal), so metreleptin can modestly alter thyroid and reproductive hormone levels, which sometimes affects dosing of thyroid replacement or hormonal contraception. Metreleptin can theoretically alter CYP450-dependent drug metabolism by modulating the obesity-associated inflammatory state, though clinically significant CYP-mediated interactions are not a major practical concern at the current indication's doses. There is no clinically important interaction between metreleptin and GLP-1 agonists, though the two are rarely combined because their indication spaces don't overlap. Concurrent metreleptin and rhGH use has not been systematically studied.
Safety Profile
Common Side Effects
Cautions
- • REMS program enrollment required in the US because of anti-metreleptin neutralizing antibody risk
- • Reported lymphoma cases in lipodystrophy patients on metreleptin — causality is contested because lipodystrophy itself carries lymphoma risk, but the signal is not dismissed
- • Insulin dose reduction often required at initiation; hypoglycemia is a real early risk in diabetic lipodystrophy patients
- • Has not been shown safe or effective in common obesity despite marketing framing
- • Pregnancy category C — insufficient human pregnancy data
What We Don't Know
Whether sub-physiologic-dose leptin replacement in the post-weight-loss state can durably prevent weight regain in common-obesity patients remains an open and interesting question — the Rosenbaum/Leibel mechanistic work suggests yes, but no therapeutic program has translated it. Whether the observed lymphoma signal in metreleptin-treated lipodystrophy patients reflects drug effect or underlying disease risk is not fully resolved.
Legal Status
United States
Metreleptin (Myalept) is FDA-approved as a prescription medication for the treatment of complications of generalized lipodystrophy. It is not approved for partial lipodystrophy, common obesity, or any other indication. US access requires enrollment of both prescriber and patient in the Myalept REMS program because of anti-metreleptin neutralizing antibody risk. It is not available through compounded pharmacies.
International
Metreleptin (Myalepta / Myalept) is approved in the EU for both generalized and partial lipodystrophy, a somewhat broader indication than the US label. Approvals and access vary across Japan, Canada, Australia, and other major markets.
Sports & Competition
Leptin itself is not specifically listed as a banned substance under the WADA Code, though it sits adjacent to the S2 class (peptide hormones and related substances). Its use is not a recognized performance-enhancement strategy. The practical reality is that access is restricted to the lipodystrophy population, so sports-doping use is essentially nonexistent.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Leptin supplements help you lose weight.
Reality
There is no such thing. Oral leptin would be destroyed by digestion (it's a protein), and 'leptin-related' supplements sold in the wellness market either contain no leptin or contain unrelated compounds marketed with the word. Even if bioavailable leptin could be taken, it would not work in common obesity because the problem is leptin resistance, not leptin deficiency — obese patients already have elevated endogenous leptin.
Myth
Leptin resistance is just broken leptin receptors.
Reality
Leptin-receptor-null genetic disease (db/db mice, LEPR mutations in humans) exists and produces severe obesity, but that is not what 'leptin resistance' refers to in common obesity. Common-obesity leptin resistance is a multi-step reduction in signal throughput — SOCS3-mediated negative feedback, PTP1B-mediated dephosphorylation, reduced BBB leptin transport, hypothalamic inflammation, and downstream melanocortin-pathway attenuation. The receptors themselves are usually intact.
Myth
Intermittent fasting or keto fixes leptin resistance.
Reality
Fasting and ketogenic diets lower serum leptin because they reduce fat mass, which is the known regulator of leptin production. Whether they improve leptin-signal responsiveness beyond the effect of fat-mass reduction is not well established. Most of the mechanistic signal is explained by adiposity reduction, not by any intervention-specific 'leptin reset' effect that the marketing language implies.
Myth
Higher leptin is always a bad sign.
Reality
Serum leptin is a marker of fat mass, not a causal driver of disease in most individuals. High leptin in obesity reflects the fat mass that produced it. Low leptin in lipodystrophy or severe caloric restriction is the pathologic state that responds to replacement. The clinical question is usually about the adiposity the leptin level reflects, not about leptin itself.
Myth
Metreleptin is a weight-loss drug for common obesity.
Reality
Metreleptin is approved only for generalized lipodystrophy — a rare condition where patients do not produce adequate adipose tissue and therefore have pathologically low leptin. In common obesity, leptin is already elevated and metreleptin has not shown meaningful efficacy. The 1999 Heymsfield JAMA trial effectively ended the common-obesity development program over two decades ago.
Published Research
12 studiesLong-term efficacy and safety of metreleptin in patients with generalized lipodystrophy
Brown et al. 2018 Endocrine — long-term follow-up of metreleptin in generalized lipodystrophy, covering both efficacy (sustained metabolic and liver improvements) and the safety signals (neutralizing antibodies, lymphoma reports) that drive the REMS program.
Mechanisms of leptin action and leptin resistance
Myers/Leibel/Seeley/Schwartz 2010 Trends Endocrinol Metab — comprehensive review of leptin resistance mechanisms (SOCS3, PTP1B, BBB transport, inflammation, downstream melanocortin pathway) that frames the modern understanding.
Leptin and its receptor in obesity — from discovery to translation
Münzberg 2010 Forum Nutr — focused review of hypothalamic leptin signaling and resistance pathways relevant for the current mechanistic interpretation of common obesity.
Adipokines as novel biomarkers and regulators of the metabolic syndrome
Ahima 2006 Obesity — review of leptin alongside other adipokines in metabolic syndrome, useful context for why leptin became the flagship but not the lone relevant adipokine.
Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight
Rosenbaum/Leibel et al. 2005 JCI — showed that sub-replacement-dose leptin reverses several of the adaptations to weight loss that drive regain. A key reference for the post-weight-loss-maintenance hypothesis that has never translated into a drug program.
Leptin-replacement therapy for lipodystrophy
Oral et al. 2002 NEJM — demonstrated dramatic metabolic improvements with leptin replacement in patients with severe lipodystrophy, establishing the indication that ultimately became the FDA approval for metreleptin.
Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial
Heymsfield et al. 1999 JAMA — the definitive negative trial of recombinant leptin in common obesity, showing modest dose-dependent weight loss at high subcutaneous doses with substantial injection-site reactions. Effectively ended the common-obesity leptin development program.
Effects of recombinant leptin therapy in a child with congenital leptin deficiency
Farooqi et al. 1999 NEJM — the dramatic demonstration that recombinant leptin reverses obesity in congenital leptin deficiency. One of the most compelling single-case therapeutic demonstrations in metabolic medicine.
Congenital leptin deficiency is associated with severe early-onset obesity in humans
Montague/Farooqi/O'Rahilly 1997 Nature — the first identified human cases of congenital leptin deficiency, establishing that the mouse biology translated to humans and that a real therapeutic target existed for this rare disorder.
Identification and expression cloning of a leptin receptor, OB-R
Tartaglia et al. 1995 Cell — cloned the leptin receptor (OB-R / LEPR), establishing the class I cytokine receptor family membership and enabling the subsequent decade of signaling work.
Positional cloning of the mouse obese gene and its human homologue
Zhang et al. 1994 Nature — the original cloning of the ob gene from the leptin-deficient mouse, by Jeffrey Friedman's lab at Rockefeller. One of the landmark papers in late-20th-century endocrinology.
Weight-reducing effects of the plasma protein encoded by the obese gene
Halaas et al. 1995 Science — demonstrated that recombinant leptin produces dramatic weight loss in ob/ob mice (leptin-deficient) but only modest effects in wild-type mice, foreshadowing the common-obesity disappointment that came four years later.
Quick Facts
- Class
- Adipokine
- Evidence
- Strong
- Safety
- Well-Studied
- Updated
- Apr 2026
- Citations
- 12PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.